China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

DOI: 10.1186/s40880-019-0383-7

Keywords: Advanced non-small cell lung cancer, Anlotinib, Anti-angiogenesis, Epidermal growth factor receptor, Activating anaplastic lymphoma kinase, Adverse drug reaction, National Medical Products Administration

Full-Text   Cite this paper   Add to My Lib

Abstract:

Study design of the ALTER0303 trial. NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor recepto

Full-Text